{
    "title": "DILI Diagnostic Panel",
    "component": "DILIDiagnostic",
    "props": {
        "pattern": {
            "classification": "Hepatocellular",
            "R_ratio": 14.13,
            "keyLabs": [
                {
                    "label": "ALT",
                    "value": "1650 U/L",
                    "note": "↑↑↑↑ (41.25x ULN)"
                },
                {
                    "label": "AST",
                    "value": "2100 U/L",
                    "note": "↑↑↑"
                },
                {
                    "label": "ALP",
                    "value": "350 U/L",
                    "note": "↑ (2.92x ULN)"
                },
                {
                    "label": "Total Bilirubin",
                    "value": "12.5 mg/dL",
                    "note": "↑↑↑ (10.42x ULN)"
                },
                {
                    "label": "INR",
                    "value": "1",
                    "note": "Normal"
                }
            ],
            "clinicalFeatures": [
                "Severe fatigue",
                "Jaundice",
                "Epigastric pain",
                "Confusion",
                "Drowsiness",
                "Asterixis",
                "Oral mucosal ulcerations"
            ]
        },
        "causality": {
            "primaryDrug": "Trimethoprim-Sulfamethoxazole",
            "contributingFactors": [
                "Methotrexate (potential synergistic toxicity)"
            ],
            "mechanisticRationale": [
                "TMP-SMX is a known cause of idiosyncratic hepatocellular DILI.",
                "TMP-SMX can inhibit folate metabolism and increase free methotrexate levels, potentially potentiating hepatotoxicity.",
                "The timeline of symptom onset following TMP-SMX initiation is highly suggestive of DILI."
            ]
        },
        "severity": {
            "features": [
                "ALT > 5x ULN",
                "ALP > 2x ULN",
                "Total Bilirubin > 2x ULN",
                "Encephalopathy (confusion, drowsiness, asterixis)"
            ],
            "prognosis": "Severe DILI with high risk of progression to acute liver failure."
        },
        "management": {
            "immediateActions": [
                "Discontinue Trimethoprim-Sulfamethoxazole",
                "Discontinue Methotrexate",
                "Initiate N-acetylcysteine",
                "Admit to ICU",
                "Aggressive supportive care"
            ],
            "consults": [
                "Hepatology",
                "Gastroenterology",
                "Hematology"
            ],
            "monitoringPlan": [
                "Frequent LFT monitoring",
                "INR monitoring",
                "Neurological status checks",
                "Monitor for signs of hepatic encephalopathy",
                "Monitor for signs of acute liver failure"
            ]
        }
    }
}